1. Schildkraut JJ. The catecholamine hypothesis of affective disorders : a review of supporting evidence. Am J Psychiatry 1965;122(5):509-522.
2. Charney DS, Menkes DB, Heninger GR. Receptor sensitivity and the mechanism of action of antidepressant treatment. Implications for the etiology and therapy of depression. Arch Gen Psychiatry 1981;38(10):1160-1180.
3. Blier P, de Montigny C. Current advances and trends in the treatment of depression. Trends Pharmacol Sci 1994;15(7):220-226.
4. Blier P, Pineyro G, el Mansari M, Bergeron R, de Montigny C. Role of somatodendritic 5-HT autoreceptors in modulating 5-HT neurotransmission. Ann N Y Acad Sci 1998;861:204-216.
5. Zanardi R, Artigas F, Franchini L, Sforzini L, Gasperini M, Smeraldi E, et al. How long should pindolol be associated with paroxetine to improve the antidepressant response? J Clin Psychopharmacol 1997;17(6):446-450.
6. Perez V, Soler J, Puigdemont D, Alvarez E, Artigas F. Grup de Recerca en Trastorns Afectius. A double-blind, randomized, placebo-controlled trial of pindolol augmentation in depressive patients resistant to serotonin reuptake inhibitors. Arch Gen Psychiatry 1999;56(4):375-379.
7. Duman RS, Heninger GR, Nestler EJ. A molecular and cellular theory of depression. Arch Gen Psychiatry 1997;54(7):597-606.
8. Kim YK. The new neurobiology of depression. Journal of Korean Society of Biological Psychiatry 2001;8(1):3-19.
9. Heim C, Nemeroff CB. The impact of early adverse experiences on brain systems involved in the pathophysiology of anxiety and affective disorders. Biol Psychiatry 1999;46(11):1509-1522.
10. Kaufman J, Plotsky PM, Nemeroff CB, Charney DS. Effects of early adverse experiences on brain structure and function : clinical implications. Biol Psychiatry 2000;48(8):778-790.
11. Steckler T, Holsboer F. Corticotropin-releasing hormone receptor subtypes and emotion. Biol Psychiatry 1999;46(11):1480-1508.
12. Arborelius L, Owens MJ, Plotsky PM, Nemeroff CB. The role of corticotropin-releasing factor in depression and anxiety disorders. J Endocrinol 1999;160(1):1-12.
13. kim YK, Choi SH, kim JY, Kim DH, Lee KJ, Shin KH. Effects of repeated stress on expression of corticotropin releasing factor type I and II receptors. J Korean Neuropsychiatr Assoc 2003;42(4):445-453.
14. Holsboer F. The rationale for corticotropin-releasing hormone receptor(CRH-R) antagonists to treat depression and anxiety. J Psychiatr Res 1999;33(3):181-214.
15. Gold PW, Drevets WC, Charney DS. New insights into the role of cortisol and the glucocorticoid receptor in severe depression. Biol Psychiatry 2002;52(5):381-385.
16. Sheline YI, Sanghavi M, Mintun MA, Gado MH. Depression duration but not age predicts hippocampal volume loss in medically healthy women with recurrent major depression. J Neurosci 1999;19(12):5034-5043.
17. Holsboer F. The corticosteroid receptor hypothesis of depression. Neuropsychopharmacology 2000;23(5):477-501.
18. Belanoff JK, Flores BH, Kalezhan M, Sund B, Schatzberg AF. Rapid reversal of psychotic depression using mifepristone. J Clin Psychopharmacol 2001;21:516-521.
19. Rothermundt M, Arolt V, Peters M, Gutbrodt H, Fenker J, Kersting A, et al. Inflammatory markers in major depression and melancholia. J Affect Disord 2001;63(1-3):93-102.
20. Kronfol Z, Remick DG. Cytokines and the brain:implications for clinical psychiatry. Am J Psychiatry 2000;157(5):683-694.
21. Maes M, Smith R, Scharpe S. The monocyte-T-lymphocyte hypothesis of major depression. Psychoneuroendocrinology 1995;20(2):111-116.
22. Kim YK, Suh IB, Kim H, Han CS, Lim CS, Choi SH, et al. The plasma levels of interleukin-12 in schizophrenia, major depression, and bipolar mania:effects of psychotropic drugs. Mol Psychiatry 2002;7(10):1107-1114.
23. Leonard BE. The immune system, depression and the action of antidepressants. Prog Neuropsychopharmacol Biol Psychiatry 2001;25(4):767-780.
24. Kim YK, Maes M. The role of cytokine network in psychological stress. Acta Neuropsychiatrica 2003;15:148-155.
25. Zalcman S, Green-Johnson JM, Murray L, Nance DM, Dyck D, Anisman H, et al. Cytokine-specific central monoamine alterations induced by interleukin-1, -2 and -6. Brain Res 1994;643(1-2):40-49.
26. Ramamoorthy S, Ramamoorthy JD, Prasad PD, Bhat GK, Mahesh VB, Leibach FH, et al. Regulation of the human serotonin transporter by interleukin-1 beta. Biochem Biophys Res Commun 1995;216(2):560-567.
27. Myint AM, Kim YK. Cytokine-serotonin interaction through IDO : A neurodegeneration hypothesis of depression. Med Hypotheses 2003;(in press).
28. Kim YK. The role of cytokines in depression and their therapeutic implication. Korean J Psychopharmacol 2000;11(4):304-312.
29. Sheline YI. 3D MRI studies of neuroanatomic changes in unipolar major depression:the role of stress and medical comorbidity. Biol Psychiatry 2000;48(8):791-800.
30. Drevets WC. Neuroimaging studies of mood disorders. Biol Psychiatry 2000;48(8):813-829.
31. Nestler EJ, Barrot M, DiLeone RJ, Eisch AJ, Gold SJ, Monteggia LM. Neurobiology of depression. Neuron 2002;34(1):13-25.
32. Duman RS. Synaptic plasticity and mood disorders. Mol Psychiatry 2002;7:Suppl 1. S29-S34.
33. Takahashi M, Terwilliger R, Lane C, Mezes PS, Conti M, Duman RS. Chronic antidepressant administration increases the expression of cAMP-specific phosphodiesterase 4A and 4B isoforms. J Neurosci 1999;19(2):610-618.
34. Farvolden P, Kennedy SH, Lam RW. Recent developments in the psychobiology and pharmacotherapy of depression : optimising existing treatments and novel approaches for the future. Expert Opin Investig Drugs 2003;12(1):65-86.